Muscle weakness with ageing is almost inevitable, generally beginning to manifest beyond the age of 40, and is usually unstoppable. It can lead to reduced mobility, increased risk of falling, injury, and even death. But “you’re just getting old” is not a sufficient diagnosis. Specific causes of neuromuscular symptoms may explain progressive muscle weakness, and should be investigated for potential treatment.

Muscle Ageing, Inclusion-Body Myositis and Myopathies explores the clinical and pathological expression of muscle weakness in aging persons. Case studies demonstrate how physicians can more accurately diagnose weakening elderly patients and make better management decisions.

It also explores sporadic inclusion-body myositis and hereditary inclusion-body myopathies. The former, the most common progressive muscle disease in the over 50s, is frequently under-diagnosed and, with the increasing population of aged individuals, is presenting a greater challenge. This disease of muscle has pathological similarities with the well-known Alzheimer and Parkinson brain diseases.

Edited and written by a leading international cast of authors, Muscle Ageing, Inclusion-Body Myositis and Myopathies provides a state-of-the-art guide to ageing-associated neuromuscular disorders. It should be in the hands of all those involved in the care of aging and muscle-weakened patients.
Part 1 Muscle Ageing
1 Ageing of the human neuromuscular system: Pathological aspects (W .King Engel and Valerie Askanas).

2 Aging of the human neuromuscular system: Clinical considerations (W. King Engel and Valerie Askanas).

3 Aging of the human neuromuscular system: Patient vignettes (W. King Engel, Shalini Mahajan, Valerie Askanas).

4 Mitochondrial changes in ageing with particular reference to muscle, and possible clinical consequences (Salvatore DiMauro, Eric Schon, Michio Hirano).

5 Protein degradation in ageing cells and mitochondria: relevance to the neuromuscular system (Jenny Ngo and Kelvin Davies).

6 Human muscle protein metabolism in relation to exercise and aging: potential therapeutic applications Micah J. Drummond, Blake B. Rasmussen).

Part 2 Sporadic Inclusion-Body Myositis (s-IBM)

7 Pathogenesis of sporadic inclusion-body myositis (Valerie Askanas, W. King Engel, Anna Nogalska).

8 Inflammatory and autoimmune features of inclusion-body myositis (Marinos Dalakas).

9 Clinical symptoms, physical findings and diagnostic investigations (Frank Mastaglia).

10 Pathologic diagnostic criteria of s-IBM and h-IBMs muscle biopsies (Valerie Askanas and W. King Engel).

Part 3 Hereditary Inclusion-Body Myopathies (h-IBM)

11Function and mutations of the GNE gene leading to DMRV/h-IBM, animal models, and potential treatments (May Malicdan, Satoru Noguchi, Ichizo Nishino).

12 Clinical and ethnic spectrum, laboratory data and epidemiology of h-IBM due to GNE mutations (Zohar Argov, Ishizo Nishino, Ikiyo Nonaka).

13& Consequences of the h-IBM characteristic GNE mutations on muscle proteins in vivo and in vitro (Aldobrando Broccolini and Massimiliano Mirabella).

14 Function and structure of VCP mutations leading to h-IBM (Cezary Wojcik).

15Clinical spectrum, including myopathy, Paget’s disease and fronto-temporal dementia; experimental models of VCP mutations, and potential treatments (Virginia Kimonis).

16 Animal models of h-IBM due to VCP mutation (Nisha M. Badders and Paul Taylor).
This title is available for license in the following territories:

This title is can be found in the following categories: